“A
Randomized, Multi-Center, Open-Label, Dose-Ranging Study
Comparing
the Safety and Efficacy of Xxxx 3.75 mg in Women with
Endometriosis-Associated
Pain.”
“A
Multi-Center, Controlled, Randomized Trial Comparing the Safety and
Efficacy
of Xxxx to Xxxx in Women with Endometriosis-Associated
Pain.”
“A
Double-Blind, Randomized, Multicenter, Parallel Group Study
Comparing
the Therapeutic Equivalence and Safety of Xxxx Xxxx 4%
Vaginal
Cream (Perrigo) with Xxxx Vaginal Cream (McNeil Ortho) in the
Treatment
of Vulvovaginal Candidiasis.”
“A
Randomized, Comparative, Multicenter, Safety and Contraceptive
Efficacy
Study of Two Xxxx Xxxx/Xxxx Estradiol Regimens, and One
Xxxx
Xxxx/Xxxx Estradiol Regimen (RWJ-10131) and Xxxx Fe 1/20.”
“A
Phase II, Randomized, Double-Blind Parallel Group Study to Evaluate
The
Safety and Efficacy of Xxxx in Patients with Xxxx Xxxx.”
“A
Randomized, Placebo-Controlled, Double-Blind, Parallel-Group
Clinical
Study to assess the effect of six months of repeated daily oral
500
and 1000 mg doses of Xxxx (INS-1) on the ovulatory endocrine and Metabolic
abnormalities of women with PCOS.”
“A
Randomized, Double-Blind, Dose-Ranging, Parallel-Group Study
To
Compare the Safety and Efficacy of Xxxx (CE10) (0.3, 0.625, and 1.25
mg
modified release) with Placebo in Postmenopausal Women Suffering
From
Moderate to Severe Vasomotor Symptoms.”
“A Dose-Range-Finding, Double-Blind, Randomized Placebo Controlled,
Multicenter, Active-Comparator Study to Determine the Effect of Xxxx
In Postmenopausal Women With Predominantly Urge Urinary
Incontinence.”
“Safety
and Efficacy Comparison of Xxxx 0.75% Vaginal Cream and
Xxxx
In Patients With Bacterial Vaginosis: A Multicenter, Randomized,
Single-Blinded,
Parallel-Group Study.”
“A
Mulitcenter, Randomized, Parallel-Group, Investigator-Blinded Study
to
Compare the Safety and Efficacy of Xxxx 1 Combination Pack in
Bedtime
versus Daytime Administration.”
“A
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,
Fixed
Dose, Multicenter Study to Evaluate the Efficacy, Safety and
Toleration
of Oral Xxxx Administered for 12 weeks to Pre-Menopausal
Women
Who Have Been Diagnosed with Female Sexual Arousal
Disorder.”
“A
Randomized, Double-Blind, Placebo-Controlled, Fixed Dose,
Mulitcenter
Study to Evaluate the Efficacy, Safety and Toleration of Oral
Xxxx
Administered for 12 weeks to Post-Menopausal Women Who have
Been
Diagnosed with Female Sexual Arousal Disorder.”
“A
Phase III, Mulitcenter, Open-Label Study to Evaluate the Safety and
Efficacy
of Xxxx 90mcg and Xxxx 20mcg in a Continuous Daily Regimen
For
Oral Contraception.”
“A
Phase II, Randomized, Double-Parallel Group Study to Evaluate the
Safety
and Efficacy of Xxxx in Patients with Uterine Leiomyomata.”
“Double-Blind
Investigation of the Efficacy and Safety of Continuous
Transdermal
1% 17 B-Xxxx in Combination with Xxxx Compared with
Continuous
Transdermal 1% 17 B-Xxxx Alone for Prevention of
Endometrial
Hyperplasia in Post-Menopausal Women.
“A
Double-Blind, Randomized, Placebo-Controlled Study of the safety
And
Efficacy of Xxxx and Xxxx Vaginal Inserts with Vaginal Atrophy.”
“A Randomized Double-Blind, Placebo-Controlled, Parallel-Group,
Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Daily
Oral Administration
of 10 mg of Xxxx Versus Placebo in Male and Female Subjects With
Overactive Bladder.”
“An
Open-Label, Long-Term Tolerability Study of Daily Oral Administration
of
10
mg Xxxx in Male and Female Subjects with Overactive Bladder.”
“A
Phase II, Randomized Study of Xxxx Versus Placebo and Xxxx in
Post-menopausal
Women with Osteopenia: Evaluation of the Dose Response
Relationship
of Xxxx on Markers of Skeletal and Lipid Metabolism and Bone
Mineral
Density.”
“A
Mulitcenter, Randomized, Double-Blind, One Year Safety and Efficacy
Study
of
Three Doses of an Xxxx capsule in the Prevention of Estrogen-induced
Endometrial
Hyperplasia in Post-Menopausal Women with Intact Uteri.”
“ A
Prospective, Randomized, Double-Blind, Placebo-Controlled Evaluation
of
Topical
Xxxx Administered at Home for the Treatment of Premenopausal Women
With
Female Sexual Arousal Disorder.”
“A
Double-Blind, Placebo-Controlled Study of Urinary Frequency and Urgency
Using Xxxx Xxxx 20 mg Tablets, Twice Daily, for 12 weeks Followed by
a
6-Month,
Open-label Treatment Phase in Patients with Overactive Bladder.”
“Xxxx
versus Placebo in the Relief of Stress Incontinence.”
“A
Multicenter, Double-Blind Comparison of Xxxx H.S. vs Estrogen Alone
In
the Treatment of Menopausal Women Complaining of Loss of Sexual Interest/
Desire.”
“A
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center
Study to Assess the Efficacy and Safety of Daily Oral Administration
of 5 and 10
Mg
Xxxxx in Patients Not Previously Exposed to Anticholinergic Drugs for the
Treatment
of Urgency Associated with Overactive Bladder”
“A Multi-center, Randomized, Parallel-group, Investigator-blinded Study
to Compare
the Safety, Therapeutic Efficacy, and Vulvovaginal Symptomatic Relief Of
a single Vaginal Dose of Xxxx 500mg Suppository compared to a 7-Day Dose Of
Miconazole Nitrate 2% vaginal cream in the Treatment of Vulvovaginal Candidiasis
“A
multi-center, double-blind, double-dummy, randomized, placebo-controlled
study
comparing a 2.2 mg 17 beta-estradiol/0.69 mg levonorgestrel combination
transdermal
patch, and a 1 mg 17 beta-estradiol transdermal patch with a placebo
patch
in postmenopausal women to determine the lowest effective dose of
estradiol
for the relief of moderate to severe hot flushes”
“A Multi-center, Randomized,
Parallel-group, Investigator-blinded Study to Compare the Safety, Therapeutic
Efficacy, and Vulvovaginal Symptomatic Relief of a single Vaginal Dose
of Xxxx 500 mg Suppository compared to a 7-Day Dose of Miconazole Nitrate
2% Vaginal Cream in the Treatment of Vulvovaginal Candidiasis.
“A Multi-center, Double-blind, Double-dummy, Randomized,
Placebo-controlled Study Comparing a 2.2mg 17 beta-estradiol/0.69
mg levonorgestrel combination transdermal patch, and a 1 mg 17
beta-estradiol transdermal patch with a placebo patch in postmenopausal
women to determine the lowest effective dose of estradiol for the
relief of moderate to severe hot flashes.”
“ A Validation Study of the Sexual Interest Questionnaire
(SIQ).”
“ A 12 month double-blind, randomized, parallel-group, placebo-controlled,
multi-center trial to investigate the efficacy and safety of Xxxx
Low Dose for the treatment of postmenopausal atrophic vaginitis
symptoms.”
“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group
Study Comparing Xxxx 2%/Xxxx 2% Vaginal Cream with Clindesse, Gynazole-1,
and Placebo in the Treatment of Subjects with Mixed Bacterial Vaginosis/Vulvovaginal
Candidiasis Infections.”
“Comparison of the Safety and Efficacy of a Unique Intravenous
Iron Preparation (Xxxx) versus Oral Iron in the Treatment of Iron
Deficiency Anemia Secondary to Heavy Uterine Bleeding.”
“A Double-Blind, Randomized, 6-month Evaluation of the Safety
and Efficacy of Topical Xxxx in Hysterectiomized Women with Female
Sexual Arousal Disorder.”
“A 12 Month, Open Label, Multicenter Study to Evaluate the
Safety of a 1.3 g Oral Dose of a New Modified-Release Xxxx Formulation
Administered Three Times Daily as Needed for up to 5 Days During
The Menstrual Cycle in Women with Heavy Menstrual Bleeding Associated
with Menorrhagia.” |
